<code id='41B825FEFE'></code><style id='41B825FEFE'></style>
    • <acronym id='41B825FEFE'></acronym>
      <center id='41B825FEFE'><center id='41B825FEFE'><tfoot id='41B825FEFE'></tfoot></center><abbr id='41B825FEFE'><dir id='41B825FEFE'><tfoot id='41B825FEFE'></tfoot><noframes id='41B825FEFE'>

    • <optgroup id='41B825FEFE'><strike id='41B825FEFE'><sup id='41B825FEFE'></sup></strike><code id='41B825FEFE'></code></optgroup>
        1. <b id='41B825FEFE'><label id='41B825FEFE'><select id='41B825FEFE'><dt id='41B825FEFE'><span id='41B825FEFE'></span></dt></select></label></b><u id='41B825FEFE'></u>
          <i id='41B825FEFE'><strike id='41B825FEFE'><tt id='41B825FEFE'><pre id='41B825FEFE'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:52272
          Cigna Healthcare's logo on a phone
          Adobe

          CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon.

          A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.

          advertisement

          The case is a prominent example of why the health care industry, and corporate America writ large, does not want noncompetes to go away. In April, the Federal Trade Commission approved a nationwide ban on most such agreements, which prevent workers from moving to other jobs, but companies and corporate lobbying groups have already sued to squash the ban.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          What AstraZeneca
          What AstraZeneca

          AstraZenecasaidFridayitwillbuyupagroupofearly-stagegenetherapiesfromPfizer,buckingatrendofdrugmakers

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          'Weather

          8:18PresidentJoeBidendeliversremarksonextremeheatconditions,fromtheSouthCourtAuditoriumontheWhiteHou